Gene Polymorphism-related Differences in the Outcomes of Abiraterone for Prostate Cancer: a Systematic Overview

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 Jun 7

PMID 34094659

Citations 2

Authors

Min Liu

Hongzhe Shi

Jiaqing Yan

Yuan Zhang

Yinglin Ma

Kaidi Le

Zhongdong Li

Nianzeng Xing

Guohui Li

Affiliations

Soon will be listed here.

Abstract

Numerous prostate cancer (PC) associated genes have been reported in previous genome-wide association studies. Elucidation of prostate cancer pharmacogenomics have enhanced studies into the impact of germline genetic changes on treatment, in addition to evaluating related genomic alterations and biomarkers in prostate tumor tissues. Currently, Abiraterone (Abi) is used as one of the therapeutic options for PC. In this article, germline variants that have been associated with responses to Abi in patients with advanced PC are summarized. These include biomarker genes such as and that are involved in homologous recombination, as well as in gene expression mutations in important signaling pathways, such as WNT and Abi metabolic pathways.

Citing Articles

Frequency of TNFalpha, IL17RA, and Act1 Genetic Polymorphisms in a Population with Psoriasis Compared with Healthy Individuals: Results in a Multiracial Population in Rio de Janeiro, Brazil.

Sampaio A, Romana-Souza B, Cabral de Almeida Monteiro H, Oliveira da Silva C, Azulay-Abulafia L Acta Derm Venereol. 2025; 105:adv42017.

PMID: 40052720 PMC: 11904834. DOI: 10.2340/actadv.v105.42017.

Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis.

Lai Y, Liu C, Wang S, Huang S, Cho Y, Bao B Cancers (Basel). 2022; 14(6).

PMID: 35326723 PMC: 8946240. DOI: 10.3390/cancers14061565.

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.

Poon D, Chan K, Chan T, Cheung F, Lam D, Lam M Cancers (Basel). 2022; 14(2).

PMID: 35053569 PMC: 8773846. DOI: 10.3390/cancers14020407.

References

Kato S, Hayakawa Y, Sakurai H, Saiki I, Yokoyama S . Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci. 2013; 105(3):281-9. PMC: 4317934. DOI: 10.1111/cas.12336. View

Johnson E, Nussenzveig R, Agarwal N, Swami U . Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics. 2019; 21(1):75-81. DOI: 10.2217/pgs-2019-0125. View

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Nakazawa M . Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015; 1(5):582-91. PMC: 4537351. DOI: 10.1001/jamaoncol.2015.1341. View

Mostaghel E, Marck B, Plymate S, Vessella R, Balk S, Matsumoto A . Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17(18):5913-25. PMC: 3184252. DOI: 10.1158/1078-0432.CCR-11-0728. View

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M . Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015; 26(9):1859-1865. PMC: 4551160. DOI: 10.1093/annonc/mdv282. View

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson P, True L . Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6(11):e27970. PMC: 3219707. DOI: 10.1371/journal.pone.0027970. View

Sepe P, Verzoni E, Miodini P, Claps M, Ratta R, Martinetti A . Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers (Basel). 2019; 11(7). PMC: 6678845. DOI: 10.3390/cancers11070980. View

Hofland J, van Weerden W, Dits N, Steenbergen J, van Leenders G, Jenster G . Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010; 70(3):1256-64. DOI: 10.1158/0008-5472.CAN-09-2092. View

10.

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

11.

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

12.

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T . SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29(18):2565-73. PMC: 3138634. DOI: 10.1200/JCO.2010.31.2405. View

13.

Shi Q, Zhu Y, Ma J, Chang K, Ding D, Bai Y . Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Mol Cancer. 2019; 18(1):170. PMC: 6878651. DOI: 10.1186/s12943-019-1096-x. View

14.

Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J . The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer. J Urol. 2017; 199(3):734-740. DOI: 10.1016/j.juro.2017.09.076. View

15.

Geng C, He B, Xu L, Barbieri C, Eedunuri V, Chew S . Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013; 110(17):6997-7002. PMC: 3637757. DOI: 10.1073/pnas.1304502110. View

16.

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong S, Wang X . Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2016; 23(3):726-734. PMC: 5675562. DOI: 10.1158/1078-0432.CCR-16-1070. View

17.

Kumar A, Coleman I, Morrissey C, Zhang X, True L, Gulati R . Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22(4):369-78. PMC: 5045679. DOI: 10.1038/nm.4053. View

18.

Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X . AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol. 2014; 9:42. PMC: 3939640. DOI: 10.1186/1746-1596-9-42. View

19.

Ryan C, Smith M, Fizazi K, Saad F, Mulders P, Sternberg C . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3.... Lancet Oncol. 2015; 16(2):152-60. DOI: 10.1016/S1470-2045(14)71205-7. View

20.

Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Itsumi M, Inokuchi J . SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy. Eur J Cancer. 2015; 51(14):1962-9. DOI: 10.1016/j.ejca.2015.06.122. View